PNC Financial Services Group Inc. increased its stake in BioScrip Inc. (NASDAQ:BIOS) by 368.4% during the second quarter, Holdings Channel reports. The institutional investor owned 74,362 shares of the company’s stock after buying an additional 58,486 shares during the period. PNC Financial Services Group Inc. owned about 0.11% of BioScrip worth $190,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. EAM Investors LLC bought a new position in BioScrip during the second quarter valued at about $1,388,000. Gabelli Funds LLC raised its position in BioScrip by 23.8% in the second quarter. Gabelli Funds LLC now owns 14,483,253 shares of the company’s stock valued at $36,932,000 after buying an additional 2,785,536 shares in the last quarter. Teton Advisors Inc. raised its position in BioScrip by 73.6% in the second quarter. Teton Advisors Inc. now owns 1,136,701 shares of the company’s stock valued at $2,899,000 after buying an additional 482,000 shares in the last quarter. Gamco Investors INC. ET AL raised its position in BioScrip by 7.8% in the second quarter. Gamco Investors INC. ET AL now owns 904,402 shares of the company’s stock valued at $2,306,000 after buying an additional 65,050 shares in the last quarter. Finally, M&T Bank Corp bought a new position in BioScrip during the second quarter valued at about $204,000. 85.65% of the stock is owned by hedge funds and other institutional investors.
Shares of BioScrip Inc. (NASDAQ:BIOS) traded down 0.90% during trading on Thursday, reaching $3.30. The company’s stock had a trading volume of 781,785 shares. The stock’s market capitalization is $375.80 million. BioScrip Inc. has a 12-month low of $1.19 and a 12-month high of $3.43. The firm’s 50-day moving average is $2.79 and its 200-day moving average is $2.61.
BioScrip (NASDAQ:BIOS) last released its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.05. The business earned $232.50 million during the quarter, compared to analyst estimates of $229.58 million. The business’s revenue for the quarter was down 11.4% on a year-over-year basis. Equities analysts expect that BioScrip Inc. will post ($0.27) earnings per share for the current year.
Separately, Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a research report on Friday, August 12th.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.